CD274 and neoplasm: In addition, studies have revealed that the positive expression rate of programmed cell death ligand 1 (PD-L1) in tumor cells is relatively high (about 45%) among LCLC patients, suggesting that PD-1/PD-L1 inhibitors could serve as potential therapeutic targets for LCLC (26, 27).